|   |
|---|
|   |  |
| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|   |
|---|
|   |  |
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|                                                               |
|---------------------------------------------------------------|
|                                                               |  |  |  |  |
| Delaware                                                      |   | 2834 |   | 20-8179278 |
| (State or Other Jurisdiction ofIncorporation or Organization) |   | (Primary Standard IndustrialClassification Code Number) |   | (I.R.S. EmployerIdentification Number) |

|                                |
|--------------------------------|
|                                |  |  |  |  |  |  |
| Large accelerated filer o |   | Accelerated filer o |   | Non-accelerated filer x  (Do not check if asmaller reporting company) |   | Smaller reporting company o |

----

|               |
|---------------|
|               |  |  |
| Part III      |
| Item 10. | Directors. Executive Officers and Corporate Governance | 3 |
| Item 11. | Executive Compensation | 8 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 13 |
| Item 13.      | Certain Relationships and Related Transactions, and Director Independence | 14 |
| Item 14.      | Principal Accounting Fees and Services | 16 |
| Part IV       |
| Item 15.      | Exhibits and Financial Statement Schedules | 17 |

----

|                                  |
|----------------------------------|
|                                  |  |  |  |  |  |
| Executive Officers and Directors |   | Age |   | Position |
| Scott Tarriff                    |   | 55 |   | President and Chief Executive Officer, Director  |
| David E. Riggs                   |   | 62 |   | Chief Financial Officer |
| Steven L. Krill, Ph.D.           |   | 55 |   | Chief Scientific Officer |
| Paul Bruinenberg, M.D.           |   | 54 |   | Chief Medical Officer |
| Peter Grebow, Ph.D.              |   | 67 |   | Executive Vice President, Research and Development |
| Jay Moorin                       |   | 63 |   | Chairman of the Board, Director |
| Steven Ratoff                    |   | 72 |   | Director |
| Sander Flaum                     |   | 77 |   | Director |
| Michael Graves                   |   | 52 |   | Director |
| Alain Schreiber, M.D.            |   | 59 |   | Director |

----

----

|         |                                                                                                                                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Class I, which consists of Michael Graves and Alain Schreiber, whose terms will expire at our annual meeting of stockholders to be held in 2015; |

|         |                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Class II, which consists of Sander Flaum and Scott Tarriff, and whose terms will expire at our annual meeting of stockholders to be held in 2016; and |

|         |                                                                                                                                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Class III, which consists of Steven Ratoff and Jay Moorin, and whose terms will expire at our annual meeting of stockholders to be held in 2017. |

----

|         |                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors; |

|         |                                                                                                                                      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services; |

|         |                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------|
| • | monitoring the rotation of partners of our independent auditors on our engagement team as required by law; |

|         |                                                                                                                                                                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor; |

|         |                                                                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing our annual and quarterly financial statements and reports, and discussing the statements and reports with our independent auditors and management; |

|         |                                                                                                                                                                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls; |

|         |                                                                                                                                       |
|---------|---------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing with management and our auditors any earnings announcements and other public announcements regarding material developments; |

|         |                                                                                                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters; |

|         |                                                                           |
|---------|---------------------------------------------------------------------------|
| • | preparing the report that the SEC requires in our annual proxy statement; |

|         |                                                                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and providing oversight of any related-person transactions in accordance with our related person transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics; |

|         |                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; |

|         |                                                          |
|---------|----------------------------------------------------------|
| • | reviewing on a periodic basis our investment policy; and |

|         |                                                                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter. |

----

|         |                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing, modifying and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding) our overall compensation strategy and policies; |

|         |                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------|
| • | reviewing and approving the compensation and other terms of employment of our executive officers; |

|         |                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and approving performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; |

|         |                                                                                                                                                                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; |

|         |                                                                                                                                                                                                                                            |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; |

|         |                                                                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding) the type and amount of compensation to be paid or awarded to our non-employee board members; |

|         |                                                                                                                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | establishing policies with respect to votes by our stockholders to approve executive compensation as required by Section 14A of the Exchange Act and determining our recommendations regarding the frequency of advisory votes on executive compensation; |

|         |                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange Act; |

|         |                                           |
|---------|-------------------------------------------|
| • | administering our equity incentive plans; |

|         |                                                                         |
|---------|-------------------------------------------------------------------------|
| • | establishing policies with respect to equity compensation arrangements; |

|         |                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation policy and strategy in achieving expected benefits to us; |

|         |                                                                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers; |

|         |                                                            |
|---------|------------------------------------------------------------|
| • | reviewing the adequacy of its charter on a periodic basis; |

|         |                                                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------------------------|
| • | reviewing with management and approving our disclosures in our periodic reports or proxy statements to be filed with the SEC; |

|         |                                                                               |
|---------|-------------------------------------------------------------------------------|
| • | preparing the report that the SEC requires in our annual proxy statement; and |

|         |                                                                                           |
|---------|-------------------------------------------------------------------------------------------|
| • | reviewing and assessing on an annual basis the performance of the compensation committee. |

|         |                                                                                                                                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| • | identifying, reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors; |

|         |                                                                               |
|---------|-------------------------------------------------------------------------------|
| • | determining the minimum qualifications for service on our board of directors; |

|         |                                                                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | evaluating director performance on the board and applicable committees of the board and determining whether continued service on our board is appropriate; |

|         |                                                                                               |
|---------|-----------------------------------------------------------------------------------------------|
| • | evaluating, nominating and recommending individuals for membership on our board of directors; |

|         |                                                                                              |
|---------|----------------------------------------------------------------------------------------------|
| • | evaluating nominations by stockholders of candidates for election to our board of directors; |

|         |                                                                                  |
|---------|----------------------------------------------------------------------------------|
| • | considering and assessing the independence of members of our board of directors; |

|         |                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | developing a set of corporate governance policies and principles, including a code of business conduct and ethics, periodically reviewing and assessing these policies and principles and their application and recommending to our board of directors any changes to such policies and principles; |

|         |                                                                                               |
|---------|-----------------------------------------------------------------------------------------------|
| • | considering questions of possible conflicts of interest of directors as such questions arise; |

|         |                                                               |
|---------|---------------------------------------------------------------|
| • | reviewing the adequacy of its charter on an annual basis; and |

|         |                                                                                           |
|---------|-------------------------------------------------------------------------------------------|
| • | annually evaluating the performance of the nominating and corporate governance committee. |

----

|         |                                                           |
|---------|-----------------------------------------------------------|
| • | Scott Tarriff, our President and Chief Executive Officer; |

|         |                                                           |
|---------|-----------------------------------------------------------|
| • | Steven L. Krill, Ph.D., our Chief Scientific Officer; and |

|         |                                              |
|---------|----------------------------------------------|
| • | David E. Riggs, our Chief Financial Officer. |

|                                                              |
|--------------------------------------------------------------|
|                                                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Name and Principal Position                                  |   | Year |   | Salary($) |   |  Bonus ($) |   | OptionAwards($) (1) |   | All OtherCompensation($) |   | Total($) |
| Scott TarriffPresident and Chief Executive Officer, Director |   | 20142013 |   | 449,633408,038 |   | -- |   | 493,639 |   | 38,738(2)35,709(2) |   | 975,932440,638 |  |   |
| Steven L. Krill, Ph.D.Chief Scientific Officer               |   | 20142013 |   | 327,405272,592 |   |  25,000- |   | 392,228116,547 |   | 12,259(2)11,282(2) |   | 747,683392,189 |  |   |
| David E. Riggs(3)Chief Financial Officer                     |   | 2014 |   | 265,929 |   | - |   | 396,357 |   | 19,620 (4) |   | 681,906 |  |   |

----

|                        |
|------------------------|
|                        |  |  |  |
| Name                   |   | Salary ($) |
| Scott Tarriff          |   | 435,000 |  |
| Steven L. Krill, Ph.D. |   | 306,000 |  |
| David E. Riggs         |   | 300,000 |  |

----

|                              |
|------------------------------|
|                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                         |   |   |   | Option awards |
|                         |   | Grant Date |   | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Exercisable(1) |   | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Unexercisable |   | OptionExercisePrice PerShare($)(2) |   | OptionExpirationDate |
| Scott Tarriff                |   | 10/02/2008 |   | 113,104 |  |   | — |  |   | 4.04 |   | 10/01/2018 |
|                         |   | 04/02/2009 |   | 124,804 |  |   | — |  |   | 4.04 |   | 04/01/2019 |
|                         |   | 05/03/2011 |   | 31,201 |  |   | — |  |   | 8.78 |   | 05/02/2021 |
|                         |   | 08/26/2014 |   | — |  |   | 75,000 |  |   | 12.63 |   | 08/25/2024 |
| David E. Riggs          |   | 11/21/2013 |   | 35,881 |  |   | — |  |   | 4.94 |   | 11/20/2023 |
|                         |   | 04/08/2014 |   | — |  |   | 17,608 |  |   | 12.67 |   | 04/07/2024 |
|                         |   | 08/26/2014 |   | — |  |   | 25,000 |  |   | 12.63 |   | 08/25/2024 |
| Steven L. Krill, Ph.D.  |   | 09/26/2011 |   | 7,800 |  |   | — |  |   | 8.78 |   | 09/25/2021 |
|                         |   | 07/12/2012 |   | 5,460 |  |   | — |  |   | 8.78 |   | 07/11/2022 |
|                         |   | 04/19/2013 |   | 21,917 |  |   | — |  |   | 4.42 |   | 04/18/2023 |
|                         |   | 04/08/2014 |   | — |  |   | 17,905 |  |   | 12.67 |   | 04/07/2024 |
|                         |   | 08/26/2014 |   | — |  |   | 40,000 |  |   | 12.63 |   | 08/25/2024 |

----

|         |                                                                                    |
|---------|------------------------------------------------------------------------------------|
| • | any breach of the director's duty of loyalty to us or our stockholders;    |

|         |                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------|
| • | any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |

|         |                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------|
| • | any act related to unlawful stock repurchases, redemptions or other distributions or payments of dividends; or |

|         |                                                                               |
|---------|-------------------------------------------------------------------------------|
| • | any transaction from which the director derived an improper personal benefit. |

|         |                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------|
| • | we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law; |

|         |                                                                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in connection with a legal proceeding to the fullest extent permitted by law; and |

|         |                                                                           |
|---------|---------------------------------------------------------------------------|
| • | the rights provided in our amended and restated bylaws are not exclusive. |

----

|                             |
|-----------------------------|
|                             |  |  |  |  |  |  |  |
| Name(1)                     |   | Fees Earned orPaid in Cash($) |   | Option Awards($)(2) |   | Total($) |
| Sander Flaum           |   |   25,000 |   | 34,019 |   | 59,019 |  |
| Jay Moorin                  |   |      54,250 |   | 34,019 |   | 88,269 |  |
| Michael Graves              |   |   20,000 |   | 34,019 |   | 54,109 |  |
| Steven Ratoff               |   |      27,375 |   | 34,019 |   | 61,394 |  |
| Alain Schreiber, M.D.  |   | 28,000 |   | 34,019 |   | 62,019 |  |

|         |                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------|
| • | an annual cash retainer of $25,000, paid quarterly for service (other than as chairman) on the board of directors; |

|         |                                                                                                                         |
|---------|-------------------------------------------------------------------------------------------------------------------------|
| • | an additional annual cash retainer of $40,000, paid quarterly, for service as chairman of the board of directors;  |

|         |                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------|
| • | an additional annual cash retainer of $20,000, paid quarterly, for service as chairman of the audit committee;  |

|         |                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------|
| • | an additional annual cash retainer of $7,500, paid quarterly, for service as chairman of the compensation |

|         |                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------|
| • | an additional annual cash retainer of $12,500, paid quarterly, for service (other than as chairman) on the audit committee;  |

|         |                                                                                                             |
|---------|-------------------------------------------------------------------------------------------------------------|
| • | an additional annual cash retainer of $7,500, paid quarterly, for service on the executive committee;  |

----

|         |                                                                                                                                                                                              |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | an additional annual cash retainer of $4,000, paid quarterly, for service (other than as chairman) on the compensation committee or the nominating and corporate governance committee;  |

|         |                                                                                                                                       |
|---------|---------------------------------------------------------------------------------------------------------------------------------------|
| • | an annual option grant to purchase 4,680 shares of our common stock vesting monthly over one year following the grant date; and  |

|         |                                                                                                                                                                                            |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | upon first joining our board of directors, an automatic initial grant of an option to purchase 9,360 shares of our common stock vesting monthly over three years following the grant date. |

|         |                                                                                  |
|---------|----------------------------------------------------------------------------------|
| • | each beneficial owner of more than five percent of the outstanding common stock; |

|         |                                                         |
|---------|---------------------------------------------------------|
| • | each of the directors and named executive officers; and |

|                                                             |
|-------------------------------------------------------------|
|                                                             |  |  |  |  |  |  |
|                                                        |   | Beneficial Ownership |
| Name and Address of Beneficial Owner (1)               |   | Number ofShares |   | Percentage ofTotal |
| 5% or greater stockholders:                                 |   |   |   |   |
| ProQuest and its affiliates(2)                              |   |  4,852,479 |  |   | 34.6 | % |
| General Electric Pension Trust(3)                           |   | 953,295 |  |   | 6.8 |  |
| Park West Asset Management LLC(4)                           |   | 711,606 |  |   | 5.1 |  |
| Named Executive Officers and Directors:                     |   |   |   |   |
| Scott Tarriff(5)                                            |   | 1,938,722 |  |   | 13.6 |  |
| David E. Riggs(6)                                           |   | 35,880 |  |   | * |  |
| Steven L. Krill, Ph.D.(7)                                   |   | 35,176 |  |   | * |  |
| Jay Moorin(8)                                               |   | 4,852,479 |  |   | 34.6 |  |
| Steven Ratoff(9)                                            |   | 33,414 |  |   | * |  |
| Sander Flaum(10)                                            |   | 43,439 |  |   | * |  |
| Michael Graves(11)                                          |   | 9,360 |  |   | * |  |
| Alain Schreiber, M.D.(12)                                   |   | 4,852,479 |  |   | 34.6 |  |
| All directors and executive officers as a group (9 persons) |   | 6,948,470 |  |   | 48.2 |  |

----

----

|         |                                      |
|---------|--------------------------------------|
| • | the risks, costs and benefits to us; |

|         |                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the impact on a director's independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; |

|         |                               |
|---------|-------------------------------|
| • | the terms of the transaction; |

|         |                                                                                       |
|---------|---------------------------------------------------------------------------------------|
| • | the availability of other sources for comparable services or products; and    |

|         |                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------|
| • | the terms available to or from, as the case may be, unrelated third parties or to or from our employees generally. |

----

|                        |
|------------------------|
|                        |  |  |  |  |  |  |  |  |
|                   |   | Year Ended September 30, |
|                   |   | 2014 |   | 2013 |
| Audit Fees (1)         |   | $ | 430,000 |  |   | $ | 82,000 |  |
| Audit Related Fees (2) |   | — |  |   | 7,000 |  |
| Tax Fees (3)           |   | 17,500 |  |   | 17,500 |  |
| All Other Fees (4)     |   | — |  |   | — |  |
| Total Fees             |   | $ | 447,500 |  |   | $ | 106,500 |  |

----

----

|               |
|---------------|
|               |  |  |  |
|          |   |   |   |
| ExhibitNumber |   | Description of Exhibit |
|          | 3.1 |  (1) | Amended and Restated Certificate of Incorporation |
|          | 3.3 |  (1) | Amended and Restated Bylaws |
|          | 4.1 |  (1) | Form of Common Stock Certificate of the Registrant |
|          | 4.2 |  (1) | Third Amended and Restated Investor Rights Agreement, dated April 11, 2013, by and among the Registrant and certain of its stockholders |
|          | 10.1 |  (1) | Form of Indemnity Agreement by and between the Registrant and its directors and officers |
|          | 10.2 | †(1) | Eagle Pharmaceuticals, Inc. 2007 Incentive Compensation Plan and Form of Stock Option Agreement thereunder |
|          | 10.3 | †(1) | Eagle Pharmaceuticals, Inc. 2014 Equity Incentive Plan and Form of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder |
|          | 10.4 | †(1) | Eagle Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan |
|          | 10.5 | †(1) | Eagle Pharmaceuticals, Inc. Non-Employee Director Compensation Policy |
|          | 10.6 | †(1) | Employment Agreement by and between the Registrant and Scott Tarriff dated March 8, 2007, as amended |
|          | 10.7 | †(1) | Offer Letter by and between the Registrant and Paul Bruinenberg dated September 7, 2011 |
|          | 10.8 | †(1) | Offer Letter by and between the Registrant and Steven Krill dated September 7, 2011 |
|          | 10.9 | †(1) | Offer Letter by and between the Registrant and David Riggs dated November 7, 2013 |
|          | 10.10 |  (1) | Lease Agreement between the Registrant and Mack-Cali Chestnut Ridge L.L.C. dated May 28, 2013, as amended on July 1, 2013 |
|          | 10.11 | (a)* (1) | Development and License Agreement, by and between the Registrant and SciDose, LLC, dated September 24, 2007, as amended March 18, 2008, May 22, 2009 and July 16, 2013 |
|          | 10.11 | (b)* (1) | Development and License Agreement, by and between the Registrant and SciDose, LLC, dated June 12, 2007, as amended March 18, 2008, March 25, 2008, December 3, 2008, May 22, 2009 and July 16, 2013 |
|          | 10.12 | *(1) | License and Sublicense Agreement, by and between the Registrant and Lyotropic Therapeutics, Inc., dated October 16, 2008 |
|          | 10.13 | *(1) | License and Development Agreement, by and between the Registrant and The Medicines Company, effective as of September 24, 2009, as amended January 2010 and September 1, 2012 |
|          | 10.14 | *(1) | Supply Agreement, by and between the Registrant and The Medicines Company, dated September 24, 2009 |
|          | 10.15 | *(1) | Agreement for the Supply of Argatroban and Topotecan, by and between the Registrant and Cipla Limited, dated December 14, 2012, as amended August 30, 2013 |
|          | 10.16 | *(1) | Supply and Distribution Agreement, by and between the Registrant and Sandoz AG, dated January 28, 2013 |
|          | 10.17 | *(1) | Development and License Agreement, by and between the Registrant and Robert One, LLC (bendamustine), dated March 18, 2008, as amended November 11, 2009 and July 16, 2013 |
|          | 10.18 | *(1) | Development and License Agreement, by and between the Registrant and Robert One, LLC (pemetrexed), dated February 13, 2009, as amended May 22, 2009, December 23, 2010 and July 16, 2013 |
|          | 23.1 |   | Consent of BDO USA, LLP, an Independent Registered Public Accounting Firm |
|          | 24.1 |   | Power of Attorney (incorporated by reference to this signature page of this Annual Report on Form 10-K) |
|          | 31.1 |   | Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
|          | 31.2 |   | Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
|          | 32.1 |   | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|          | 101.INS |   | XBRL Instance Document |
|          | 101.SCH |   | XBRL Taxonomy Extension Schema Document |
|          | 101.CAL |   | XBRL Taxonomy Extension Calculation Linkbase Document |
|          | 101.DEF |   | XBRL Taxonomy Extension Definition Linkbase Document |
|          | 101.LAB |   | XBRL Taxonomy Extension Labels Linkbase Document |
|          | 101.PRE |   | XBRL Taxonomy Extension Presentation Linkbase Document |

----

|        |
|--------|
|        |  |  |
| By:    | /s/ Scott Tarriff |   |
|   | Scott Tarriff |   |
|   | President and Chief Executive Officer |   |